GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus
- Conditions
- Hepatitis C, Chronic
- Interventions
- Biological: peginterferon alfa-2aDrug: GS-9451 Placebo
- First Posted Date
- 2011-05-19
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 351
- Registration Number
- NCT01356160
GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2011-05-13
- Last Posted Date
- 2013-12-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 141
- Registration Number
- NCT01353248
- Locations
- 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Digestive Health Specialists of the Southeast, Dothan, Alabama, United States
A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)
- Conditions
- Angina PectorisCoronary Artery DiseaseType 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2011-04-13
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT01334203
Rollover Protocol Continued Access to Tenofovir Disoproxil Fumarate (TDF) for Subjects in Taiwan
- First Posted Date
- 2011-04-13
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT01334567
Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6
- First Posted Date
- 2011-04-06
- Last Posted Date
- 2014-05-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 332
- Registration Number
- NCT01329978
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Asheville Gastroenterology Associates, Asheville, North Carolina, United States
🇺🇸St. Louis University Gastroenterology and Hepatology Clinical Research, St. Louis, Missouri, United States
First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid Tumors
- First Posted Date
- 2011-03-28
- Last Posted Date
- 2012-05-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 32
- Registration Number
- NCT01323933
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB
- First Posted Date
- 2011-03-23
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 43
- Registration Number
- NCT01320943
- Locations
- 🇩🇪
Klinikum der LMU Grosshadern, Muenchen, Germany
🇩🇪Medizinische Hochschule Hannover, Hannover, Germany
🇩🇪Universitaetsklinik Heidelberg, Heidelberg, Germany
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2012-03-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 90
- Registration Number
- NCT01316237
- Locations
- 🇺🇸
Axis Clinical Trials, Los Angeles, California, United States
🇺🇸CRI Worldwide, Philadelphia, Pennsylvania, United States
🇺🇸Advanced Clinical Research Institute, Anaheim, California, United States
Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis
- First Posted Date
- 2011-03-14
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 266
- Registration Number
- NCT01313624
- Locations
- 🇺🇸
Bay Area Chest Physicians, Clearwater, Florida, United States
🇺🇸Pulmonary and Critical Care Associates of Baltimore, Baltimore, Maryland, United States
🇺🇸Cardio Pulmonary Research at St. Luke's Hospital, Chesterfield, Missouri, United States
Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis
- First Posted Date
- 2011-03-14
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 274
- Registration Number
- NCT01314716
- Locations
- 🇨🇦
Kelowna Respiratory Research and Allergy Clinic, Kelowna, British Columbia, Canada
🇨🇦The Lung Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada
🇺🇸University of Florida, Jacksonville, Florida, United States